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Liule is known in psychiatry concerning fundamentaldisease processes. The relative absence Ilfdisease-specific rreatrnerus is therefore not surprising. Most physical treaunents in psychiatry t'l.en their therapeutic effects in a nonspecific fashion.Lack of disease spccificuy means that compromises are conrinually made between beneficial andunwanted treatment effects. Indeed, the goal nf most therapeutic developments, given lirnitationsinknowledge concerning disease processes, is nenhance wanted over unwanted effects.
Physical treatments in psychiatry, as in other mnches of medicine, aim to ameliorate, arrest. lodreverse disease processes. In practice, the arrest or reversal of psvchiarric disease is all idealistic nd rarely achieved goal. In this, psychiatry shares lDuchin common with neurology in thin symptom relief is the principal therapeutic aim.
Despite these limitations. there are man)' benrficial and effective treatments ill psychiauy. The mediationof these effects is generally ascribed to ;Iterationsin neuronal function £11 neurorcceptor lites. However, a lack of pharmacologic and diseasẽ iftcit}' means that psychiatric interventions are ssxiated with high rates of unwanted effects. Becuseof their high prevalence. neurologic side efkmare the most important hazards of psychiatric seatments.The recognition of neurologic side eff eeLS is therefore of great clinical importance.
This review examines (he prevalence. clinical presentalion, putative pathophysiology, and man1gement of neurologic side effects of psychiatric keatmems.It is not possible within the brief space ofthisarticle to cover all treatments ill psychiatry; !here fore (he focus will be on rhe more convenal and widespread treatments. These includẽ eneuroleptics, lithium. antidepressants, electroenvulsivetherapy (EeT), anxiolyucs, and psycho-.rgery.
NEUROLEPTICS
This broad group of compounds consritutes the cornerstone of pharmacologic treatment of (he psychoses, particularly schizophrenia.
The int roduction of potent antipsychotic agents into clinical practice in 1952 was associated with an almost immediate recognition that these agents could result in neurologic side effects.!" Side effects may for convenience be thought of as acute and chronic, though in reality such a division is arbitrary and artificial. There is little dispute that neuroleptics cause acute neurologic side effects, but there is controversy as LO whether they arc either necessary or sufficient causes for the emergence of chronic side effects, in particular tardive dyskinesia (TD). This question will be addressed further in considering TD. The most commonly encountered neurologic side effects of neuroleptics are summarized in Tablc I. Although TD is all undoubted effect of longtermneuroleptic treatment, there is considerable controversy as to whether the occurrence of this rondition in chronic psychiatric patients is duẽ
Ielyto the effects of neurolepucs, to the underng disease process, or 10 an interaction of drugs withthe underlying disease state.!" Central issues nthis conu'oversy are whether a condition akin lO ID occurred in the prcneurolcpric era and theiher the prevalence of the condition has insed with increasing use of ncurolcptics. There \'erylittle information on the latter point, though mere is considerable clinical evidence that condimns characterized by excess movements, akin to ,were seen in the prr-neuroleptic era. Kraepelin described abnormal movements in chronic psychotic patients thus: "Connected with these are. further, smacking and clicking of the tongue .... But besides we observe especially in the lip muscles, fine lightning-like or rhythmical twitchings. which in no way bear the stamp of voluntary movements. The same is the case in the tremor of the muscles of the mouth which appears sometimes ill speaking.
." l Iowcver, it is uncertain whether these earl)' descriptions are indeed from patients with primary schizophrenic illness or schizophrenic illness secondary to primary neurologic conditions, such as postencephalitic stales. Fu rrhermore.
TD is described in patients receiving neuroleptics for conditions other than schizophrenia, such as manic-depressive illness. III The reponed prevalence of TO in popularions of patients receiving neuroleptic medication varies from I to 40%. Discrepancies in reponed prevalence are partly attributable to variations in operauoual definitions of TO, with some early reports being based solely on the BLM triad. Other variables that may influence prevalence figures include age. duration, type, and dosage of medication. An accepted prevalence figure is 20% of patients 011 long-term neuroleptic n-eaunem.v-"
Risk factors Cor the development of the disorder that have emerged from epidemiologic surveys include age, female sex, and underlying cerebral disease or damage.:w.:l l An increased risk of developing the disorder is also reponed in patients receiving concurrent anticholinergic drugs.
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The disorder is most often seen in schizophrenic patients but also occurs in other populauons of neuroleptic-treated patients. Indeed, cOnlrary ro arguments for special association with schizophrenia, it has been suggested that patients with affective disorder exposed 1.0 neuroleptics arc at greater risk of developing the disorder."
The condition is also encountered ill postencephalitic stales, as a spontaneous condition in up to a 4uarter of the elderly population," 
ANTIDEPRESSANTS
MONOAMINE REUPTAKE 1NHlBITORS
This broad class of agents constitutes the mainstay treatment of affective disorders and includes the u-icycfics, tetracyclics, and the newer selective monoamine rcuptake inhibitors (~IAR1), such as S-hydroxvn-yptophan (5~1IT) reuptake inhibitors. Since this grouping contains a wide diversit). of pharmacologic compounds, trlany with (l broad spectrum of central effects, the range of side effects is great. However, as a general rule. these compounds are devoid of any permanent neurologic sequelae. This is somewhat surprising given 299
SHIlNARS I, NEUROLOGY VOLU~IE 10. NU~IBER 3 SEPTEMBER the structural similarity between the tricyclics and the phenothiazine ncuroleptics. Neurologic side effects at toxic levels or overdosage are largely auributable lO anticholinergic effects, which include confusion, distractability, hallucinations, slurred speech, insomnia, and coma." AI therapeutic levels, like the neurolepucs, the tricyclics and tetracyclics arc associated with peripheral aruimuscarinic effects, including dry mouth, blurred vision, delayed ejaculation. and urinary retention. Trazoclone may cause priapism and permanent irnporencc.:'? Central effects are mainly dose related and are seen especially in the elderly. Confusion, reported in 10% of patients, is possibly related to the anticholinergic effects of some MARls.
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A fine tremor is seen ill approximately 5~of patients on tricydics. but cxtrapyramidal effects proper are extremely rare. Alteration of seizure threshold is a potential side effect of all drugs in this class. Isolated cases of Nl\·IS are also reported in association with this class of antidepressants.
MONOAMINE OXIDASE INHIBITORS
This chemically broad category of drugs shares a common property of inhibiting oxidative dearninauon of monoamines. Two subclasses arc recognized, with relatively selective potencies for inhibition of monoamine oxidase (MAO) A and 13, the two subtypes of MAO enzyme. All compounds in this group are irreversible ("suicide") inhibitors of MAO.
Toxic effects are seen following overdosage and at therapeutic levels. The former consist of agitation, hyperreflexia, hyperpyrexia, hallucinations, and convulsions.
At therapeutic levels, neurologic side effects include tremor, insomnia, hallucinations, aud confusion. Peripheral neuropathy is seen in a proportion of patients exposed to the hydrazine group of MAO inhibitors.
ANTIANXIETY AGENTS
The main compounds in clinical use for the management of anxiety stales are the benzodiazepines. Indeed, they comprise the most widely prescribed psychotropic agents. Newer antianxiety compound".
particularly with affinities for central seroionerg«: receptors, arc under evaluation in clinical pra( nee. The principal adverse effects or these agents relate to their potential for causing dcpendence and abuse. Therefore a physical withdrawal syndrome, of which seizures may be a componetll.
is frequently encountered in patients taking these compounds on a medium LO long- 15 in 1986. It remains a highly controversial int vention in view of the nature of the procedure, scientific justification, and the ethical issues volved. Many practicing psychiatrists disagree tirely with its use. Those who see a role for ps)'c surgery limit its usage to patients with severe intractable anxiety, obsessional disorders, and prcssive illness that has not responded to at therapies. Procedures now in use are entirely reotactic, producing lesions of the inferior fro white matter (subcaudate tractotomy) and ante cingulate gyri. The former procedure is form cd for affective disorders, anxiety, or de sion, while the latter is indicated in intractable sessional disorders.
There are many problems in evaluating n rologic side effects of psychosurgery particulars one is dealing with an unusual and atypical po lation. Furthermore, there is a striking paucity 
